Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.
In 2006, Cohen and co-workers described in the New England Journal of Medicine that loss-of-function PCSK9 mutations are associated with low LDL-C and low prevalence of cardiovascular events.
If it makes it through development, VERVE-101 could provide a one-off alternative to a lengthening list of PCSK9 inhibitors ... dosed alongside current cholesterol drugs like statins.